An integrated approach to cardioprotection in lymphomas. Issue 6 (June 2022)

• Record Type: Journal Article
• Authors: Maraldo, Maja V; Levis, Mario; Andreis, Alessandro; Armenian, Saro; Bates, James; Brady, Jessica; Ghigo, Alessandra; Lyon, Alexander R; Manisty, Charlotte; Ricardi, Umberto; Aznar, Marianne C; Riccardo Filippi, Andrea
• Is Part Of: Lancet. Volume 9:Issue 6(2022)
• Page Start: e445
• Page End: e454
• Publication Date: 2022-06
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15005
• DOI: 10.1016/S2352-3026(22)00082-5
• Languages: English
• ISSNs: 2352-3026

Abstract

Summary: In potentially curable cancers, long-term survival depends not only on the successful treatment of the malignancy but also on the risks associated with treatment-related toxicity, especially cardiotoxicity. Malignant lymphomas affect patients at any age, with acute and late toxicity risks that could have a severe effect on morbidity, mortality, and quality of life. Although our understanding of chemotherapy-associated and radiotherapy-associated cardiovascular disease has advanced considerably, new drugs with potential cardiotoxicity have been introduced for the treatment of lymphomas. In this Review, we summarise the mechanisms of treatment-related cardiac injury, available clinical data, and protocols for optimising cardioprotection in lymphomas. We discuss ongoing research strategies to advance our knowledge of the molecular basis of drug-induced and radiation-induced toxicity. Additionally, we emphasise the potential for personalised follow-up and early detection, including the role of biomarkers and novel diagnostic tests, highlighting the role of the cardio-oncology team.